NTS231 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

16 results for “NTS231”

Trials

View all 12 →

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

220 participants · First posted Jul 11, 2025

Longitudinal Evaluation and Real-world Evidence of NT201

11 participants · First posted Feb 3, 2022

Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

37 participants · First posted Jan 8, 2007

Drugs

AST-NS2301

NTS1 recombinant antibodies

News

Nutshell Therapeutics' NTS231 Gains FDA IND Clearance as Second NRF2 Degrader to Enter Clinical Development

FDA Clears IND for Nutshell Therapeutics' Novel p53 Y220C Reactivator NTS071

Page 1 of 2